Tallac Therapeutics™ is a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer using antibody drug conjugates (ADCs). Tallac’s pipeline of oligonucleotide-based ADC candidates includes novel Toll-like Receptor Agonist Antibody Conjugates (TRAAC) to systemically deliver a potent Toll-like receptor (TLR9) agonist (T-CpG) and trigger immune activation within the tumor microenvironment. Several TRAAC molecules are in various stages of discovery and development, including two programs in the clinic.